S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:SRNE

Sorrento Therapeutics (SRNE) Stock Price, News & Analysis

$0.02
-0.01 (-25.93%)
(As of 03/1/2024 ET)
Today's Range
$0.02
$0.03
50-Day Range
$0.02
$0.15
52-Week Range
$0.16
$3.09
Volume
199,315 shs
Average Volume
52.69 million shs
Market Capitalization
$9.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Sorrento Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.41
Upright™ Environmental Score
News Sentiment
-0.13mentions of Sorrento Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.55 out of 5 stars


SRNE stock logo

About Sorrento Therapeutics Stock (NASDAQ:SRNE)

Sorrento Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company specializes in developing antibody-based therapies for cancer, autoimmune diseases, and chronic pain. Sorrento Therapeutics was founded in 1989 and has since grown into a  player in the biopharmaceutical industry, focusing on developing innovative and personalized therapies for patients.

The management team at Sorrento Therapeutics is led by Dr. Henry Ji, who serves as the company's Chairman and CEO. Dr. Ji has over 20 years of experience in the biopharmaceutical industry and has played a vital role in developing innovative Sorrento Therapeutics therapies. Other notable team members are Mike Royal, Chief Medical Officer, who has over 20 years of clinical development experience and Dr. Robert D. Allen, who has over 15 years of biotechnology industry research and preclinical development experience. 

Over the past few years, Sorrento Therapeutics has reported relevant growth in revenue. However, the company has also reported significant losses increasing year over year. The company's debt levels have varied dramatically, with assets and liabilities increasing year over year. Sorrento Therapeutics has undergone substantial changes in ownership over the past few years, with several prominent investors increasing their stakes in the company. Sorrento Therapeutics' valuation metrics align with industry peers, with a price-to-book ratio near industry averages. However, the company's price-to-earnings ratio is currently negative, typical for clinical-stage biopharmaceutical companies that have yet to reach profitability. Sorrento Therapeutics stock has been volatile in recent years, with significant price movements and changes in trading volume. The company's stock price has steadily declined over the past five years.

The biopharmaceutical industry is highly competitive, with many large, established companies and smaller, innovative players like Sorrento Therapeutics. High research and development spending levels, lengthy regulatory approval processes, and significant intellectual property protections characterize the industry. Sorrento Therapeutics faces competition from established players such as Pfizer, Merck, and Bristol-Myers Squibb, as well as smaller biotechs developing similar antibody-based therapies.

Sorrento Therapeutics has several potential growth opportunities, including developing its proprietary antibodies and other therapies for treating cancer, autoimmune diseases, and chronic pain. The company is also exploring partnerships and collaborations with other companies in the biopharmaceutical industry to help accelerate the development of its pipeline of therapies. Additionally, Sorrento Therapeutics is expanding into new markets, focusing on Asia, with significant demand for innovative treatments.

The biopharmaceutical industry is highly regulated, and Sorrento Therapeutics may face challenges in obtaining regulatory approval for its therapies. The company's financial performance has also been volatile, with significant losses reported in recent years. Sorrento Therapeutics will need to continue investing heavily in research and development to maintain its competitive position in the industry, which may strain the company's financial resources. In addition, the biopharmaceutical industry is subject to significant geopolitical and regulatory risks, which could impact Sorrento Therapeutics' operations and growth prospects.

SRNE Stock Price History

SRNE Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Sorrento Therapeutics, Inc. (0L85.L)
Sorrento Therapeutics Inc SRNEQ
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
SRNEQ Sorrento Therapeutics, Inc.
Sorrento Therapeutics (OTC: SRNE.Q)
Sorrento Therapeutics, Inc. (SRNEQ)
Why Sorrento Therapeutics Stock Is Soaring Today
See More Headlines
Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SRNE
Employees
799
Year Founded
2006

Profitability

Net Income
$-428,330,000.00
Net Margins
-818.22%
Pretax Margin
-877.48%

Debt

Sales & Book Value

Annual Sales
$60.32 million
Book Value
$0.26 per share

Miscellaneous

Free Float
459,611,000
Market Cap
$9.44 million
Optionable
Optionable
Beta
1.95

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Henry H. Ji
    Chairman, President & Chief Executive Officer
  • Shawn Sahebi
    Senior Vice President-Commercial Operations
  • Elizabeth Adkins Czerepak
    Chief Financial Officer & Executive Vice President
  • Mike A. Royal
    Chief Medical Officer
  • Robert D. Allen
    Senior Vice President-Research & Development














SRNE Stock Analysis - Frequently Asked Questions

How have SRNE shares performed in 2024?

Sorrento Therapeutics' stock was trading at $0.1235 at the beginning of 2024. Since then, SRNE shares have decreased by 83.8% and is now trading at $0.02.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRNE) was last updated on 3/4/2024 by MarketBeat.com Staff